Company news

Capricor Therapeutics, Inc. news in 2025

Capricor Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

December 16, 2025

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

December 5, 2025

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

December 4, 2025

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

December 3, 2025

Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025

November 24, 2025

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 10, 2025

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

November 4, 2025

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

November 3, 2025

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

October 31, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

September 25, 2025

Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

September 15, 2025

Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

September 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

September 15, 2025

Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR) - Contact Levi & Korsinsky Before September 15, 2025

September 9, 2025

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

September 9, 2025

Shareholders of Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

September 8, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

September 5, 2025

September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR

September 5, 2025

Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR) - Contact Levi & Korsinsky Before September 15, 2025

September 4, 2025

Investors in Capricor Therapeutics, Inc. (CAPR): Protect Your Rights - Contact Levi & Korsinsky Before September 15, 2025

August 28, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CAPR

August 28, 2025

September 15, 2025 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR) - Contact Levi & Korsinsky

August 26, 2025

Contact The Gross Law Firm by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)

August 25, 2025

Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky

August 21, 2025

September 15, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against CAPR

August 21, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

August 19, 2025

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

August 18, 2025

Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR) Investors - Contact Levi & Korsinsky Before September 15, 2025

August 18, 2025

Investors in Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

August 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

August 15, 2025

Capricor Therapeutics, Inc. (CAPR) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 15, 2025

August 14, 2025

Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)

August 12, 2025

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025

Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

August 11, 2025

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

August 8, 2025

Capricor Therapeutics Sued for Securities Law Violations - Investors Should Contact Faruqi & Faruqi for More Information - CAPR

August 6, 2025

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

August 6, 2025

Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc. (CAPR)

July 31, 2025

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy

July 28, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

July 11, 2025

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

June 20, 2025

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

June 17, 2025

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

June 11, 2025

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

May 13, 2025

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

May 6, 2025

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

May 5, 2025

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

April 1, 2025

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 19, 2025

Older news releases →

Calls in 2025

Decks in 2025